Common Stock, $0.0001 par value per share
- Symbol
- PCSA
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 8.01, 9.01 · 8-K
Processa Pharmaceuticals, Inc.
PCSANASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On November 5, 2026, Processa Pharmaceuticals, Inc. (the “Company”) issued a letter to the Company’s stockholders (the “Stockholder Letter”). A copy of the Stockholder Letter is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Company context
We are a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (“NGC”) small molecules, two of which are in, or have completed, Phase 2 trials, and one is in pre-clinical development.
Current securities
Historical securities (1)
Registered securities in this filing
Processa Pharmaceuticals, Inc. · 8-K · Filed 2026-11-05
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On November 5, 2026, Processa Pharmaceuticals, Inc. (the “Company”) issued a letter to the Company’s stockholders (the “Stockholder Letter”). A copy of the Stockholder
Letter is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Filed exhibits (1)
Exhibit 99.1 Dear Processa Stockholder, In July, Processa acquired Vidya Therapeutics and completed a concurrent private placement financing of approximately $200 million supported by leading institutional healthcare investors. This transaction established a new strategic direction for the company focused on advancing differentiated therapeutic programs for immunological and inflammatory (I&I) diseases, led by VT-7208, Vidya’s lead investigational product candidate. We believe this combination creates a meaningful opportunity for Processa and its stockholders: a lead clinical-stage program addressing large patient populations, a growing I&I pipeline, a clear development plan with multiple potential value-driving milestones, and financing expected to support the company through key development milestones. Since closing the transaction, we have begun to deliver against that plan, including advancing VT-7208 into Phase 2 development, expanding the company’s pipeline and strengthening its leadership. With this letter, we want to explain the opportunity, how we are funded to execute and what stockholders should expect next. A Lead Program Addressing Significant Unmet Need VT-7208…
Open exhibit ↗